Luye Pharma USA is showcasing Ansofaxine at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.
Ansofaxine is Luye's pipeline highlight — the first triple reuptake inhibitor with positive Phase 3 data (74-80% response rate, 52% remission). At APA, they'll be building KOL awareness ahead of an expected NDA filing. The clean tolerability profile (no sexual dysfunction, no weight gain reported) is a major differentiator vs. SSRIs/SNRIs for psychiatrists tired of managing those side effects.
Ask about: NDA filing timeline; tolerability profile data in detail (sexual dysfunction rates, weight changes); how they position vs. SNRIs (what does dopamine reuptake inhibition add clinically?); target patient profile; Phase 3 response/remission rate details. The tolerability story is incredibly compelling for psychiatrists.
First SNDRI needs differentiated evidence — VoiceVitals can objectively capture the anhedonia, motivation, and energy improvements that dopamine reuptake inhibition should uniquely deliver (beyond what SNRIs provide). ePRO+ enriches the NDA-stage evidence. The tolerability advantage (no sexual dysfunction, no weight gain) can be captured through multimodal patient-reported outcomes — real-world evidence that matters enormously to prescribers.
Set up a follow-up with Luye Pharma USA's team and Videra Health.
Email Ryan Roberts →